Design and development of novel therapeutics for coronary heart disease treatment based on cholesteryl ester transfer protein inhibition - in silico approach

被引:4
|
作者
Kostic, Tomislav [1 ]
Ilic, Marina Deljanin [2 ]
Perisic, Zoran [1 ]
Milic, Dragan [3 ]
Dordevic, Miodrag [4 ]
Golubovic, Mladjan [5 ]
Koracevic, Goran [1 ]
Martinovic, Sonja Salinger [1 ]
Zdravkovic, Snezana Ciric [1 ]
Zivic, Sasa [3 ]
Lazarevic, Milan [3 ]
Stanojevic, Dragana [1 ]
Dakic, Sonja [1 ]
Lilic, Jelena [5 ]
Veselinovic, Aleksandar [6 ]
机构
[1] Clin Ctr Nis, Clin Cardiovasc Dis, Nish, Serbia
[2] Inst Cardiovasc Prevent & Rehabil Niska Banja, Nish, Serbia
[3] Clin Ctr Nis, Clin Cardiovasc Surg, Nish, Serbia
[4] Clin Ctr Nis, Clin Endocrine Surg & Breast Surg, Nish, Serbia
[5] Clin Ctr Nis, Clin Anesthesiol & Intens Care, Nish, Serbia
[6] Univ Nis, Fac Med, Dept Chem, Bulevar Dr Zorana Dindica 81, Nish 18000, Serbia
来源
关键词
Cholesteryl ester transfer protein inhibitors; coronary heart disease therapy; QSAR; molecular modeling; drug design; MONTE-CARLO METHOD; DRUG DISCOVERY; VARIABLE SELECTION; QSAR; HDL; VALIDATION; PRINCIPLES; DOCKING; 3D-QSAR; TARGET;
D O I
10.1080/07391102.2019.1630319
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesteryl ester transfer protein (CETP) belongs to the group of enzymes which inhibition have the application in the treatment of cardiovascular diseases. This study presents QSAR modeling for a set of compounds acting as CETP inhibitors based on the Monte Carlo optimization with SMILES notation and molecular graph-based descriptors, and field-based 3D modeling. A 3D QSAR model was developed for one random split into the training and test sets, whereas conformation independent QSAR models were developed for three random splits, with the results suggesting there is an excellent correlation between them. Various statistical approaches were used to assess the statistical quality of the developed models, including robustness and predictability, and the obtained results were very good. This study used a novel statistical metric known as the index of ideality of correlation for the final assessment of the model, and the results that were obtained suggested that the model was good. Also, molecular fragments which account for the increases and/or decreases of a studied activity were defined and then used for the computer-aided design of new compounds as potential CETP inhibitors. The final assessment of the developed QSAR model and designed inhibitors was done using molecular docking, which revealed an excellent correlation with the results from QSAR modeling. Communicated by Ramaswamy H. Sarma
引用
收藏
页码:2304 / 2313
页数:10
相关论文
共 50 条
  • [21] WCC 22-Cholesteryl ester transfer protein inhibitors: A potential new therapy for coronary heart disease
    Hunt, Julianne A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [22] Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction
    Schaefer, Ernst J.
    Asztalos, Bela F.
    CURRENT OPINION IN LIPIDOLOGY, 2006, 17 (04) : 394 - 398
  • [23] Oral cholesteryl ester transfer protein (CETP) inhibitors: A potential new approach for treating coronary artery disease
    Sikorski, JA
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (01) : 1 - 22
  • [24] A Novel Missense Mutation(L296Q)in Cholesteryl Ester Transfer Protein Gene Related to Coronary Heart Disease附视频
    KeQin ZHENG SiZhong ZHANG Li ZHANG DeJia HUANG LinChuan LIAO and YiPing HOU Department of Medical Genetics West China Hospital
    Division of Human Morbid Genomics Key Laboratory ofBiotherapy ofHuman Diseases of Ministry of Education Sichuan University Chengdu China
    Department of Cardiology West China Hospital Sichuan University Chengdu China
    School of Basic and Forensic Medicine Sichuan University Chengdu China
    Acta Biochimica et Biophysica Sinica, 2004, (01) : 33 - 36
  • [25] The relationship between genetic defect of cholesteryl ester transfer protein with coronary artery disease
    Chae, IH
    Han, KH
    Choe, SC
    Kim, HS
    Park, YB
    Choi, YS
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 65 - 65
  • [26] Cholesteryl ester transfer protein inhibitors as potential new therapies for coronary artery disease
    Sikorski, James A.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (06) : 753 - 772
  • [27] Effects on Lipids and Safety Following Cessation of Treatment with Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
    Gotto, Antonio M., Jr.
    Cannon, Christopher P.
    Shah, Sukrut
    Liu, Sherry
    Li, Susie
    Stepanavage, Michael
    Brinton, Eliot
    Davidson, Michael
    Dansky, Hayes
    Mitchel, Yale
    Barter, Philip
    CIRCULATION, 2011, 124 (21)
  • [28] Chemometric modeling and pharmacophore mapping in coronary heart disease: 2-arylbenzoxazoles as cholesteryl ester transfer protein inhibitors
    Jana, Dhritiman
    Halder, Amit Kumar
    Adhikari, Nilanjan
    Maiti, Milan Kumar
    Mondal, Chanchal
    Jha, Tarun
    MEDCHEMCOMM, 2011, 2 (09) : 840 - 852
  • [29] Carriers of three polyrnorphisms of cholesteryl ester transfer protein gene are at increased risk to coronary heart disease in a Chinese population
    Zheng, KQ
    Zhang, SZ
    Zhang, L
    He, Y
    Liao, LC
    Hou, YP
    Huang, DJ
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 103 (03) : 259 - 265
  • [30] Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction
    Schaefer, Ernst J.
    Asztalos, Bela F.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (11): : 25N - 31N